MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical company valued at $58.63 million, has published results from a preclinical study on its second cancer vaccine candidate, IO112, which ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on regulatory guidance for ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS ...

Co. Ltd. has identified eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer.

Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the identification of heteroaromatic ring compounds acting as membrane-associated tyrosine-and threonine-specific Cdc2-inhibitory ...